These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 13961817)

  • 21. FEATURES OF EXPERIMENTAL NEUROSIS PRODUCED BY LYSERGIC ACID DIETHYLAMINE.
    IVANOVA RA; LARICHEVA KA; MILSHTEIN GI
    Fed Proc Transl Suppl; 1964; 23():268-71. PubMed ID: 14145650
    [No Abstract]   [Full Text] [Related]  

  • 22. [FUNDAMENTALS OF A CONDITIONAL-GENETIC PSYCHOPATHOLOGY AS EXEMPLIFIED BY EXPERIMENTAL PSYCHOSIS].
    LEUNER H
    Nervenarzt; 1963 May; 34():198-206. PubMed ID: 14157764
    [No Abstract]   [Full Text] [Related]  

  • 23. Lysergic acid diethylamide (LSD-25) antagonists. II. Development of tolerance in man to LSD-25 by prior administration of MLD-41 (1-methyl-d-lysergic acid diethylamide).
    ABRAMSON HA; SKLAROFSKY B; BARON MO; FREMONT-SMITH N
    AMA Arch Neurol Psychiatry; 1958 Feb; 79(2):201-7. PubMed ID: 13497364
    [No Abstract]   [Full Text] [Related]  

  • 24. Blocking of LSD reaction by premedication with Niamid.
    Grof S; Dytrych Z
    Act Nerv Super (Praha); 1965 Aug; 7(3):306. PubMed ID: 5882136
    [No Abstract]   [Full Text] [Related]  

  • 25. [CLINICAL ASPECTS OF MODEL PSYCHOSES].
    JOHNSEN G
    Nord Psykiatr Tidsskr; 1964; 18():16-24. PubMed ID: 14132834
    [No Abstract]   [Full Text] [Related]  

  • 26. Follow-up studies in group and individual LSD psychotherapy.
    Hausner M; Dolezal V
    Act Nerv Super (Praha); 1966 Feb; 8(1):87-95. PubMed ID: 5913553
    [No Abstract]   [Full Text] [Related]  

  • 27. [Lysergic acid diethylamide. A clinical and psychological study].
    BRATTEMO CE; LASSENIUS B
    Nord Med; 1963 Feb; 69():193-7. PubMed ID: 14015013
    [No Abstract]   [Full Text] [Related]  

  • 28. [LSD 25 and existence].
    Gamna G
    G Psichiatr Neuropatol; 1966; 94(1):121-44. PubMed ID: 5329914
    [No Abstract]   [Full Text] [Related]  

  • 29. [From LSD to selfhypnosis in catathymic experience, art and therapy].
    Grünholz G
    Z Psychother Med Psychol; 1971 Mar; 21(2):74-86. PubMed ID: 5573989
    [No Abstract]   [Full Text] [Related]  

  • 30. Hyperthermic effects of D-lysergic acid diethylamide (LSD) and its derivatives in rabbits and rats.
    Hashimoto H; Hayashi M; Nakahara Y; Niwaguchi T; Ishii H
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):314-21. PubMed ID: 303504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of lysergic acid diethylamide in psychoneuroses; preliminary observations and principles of diagnostic and therapeutic evaluation].
    GIBERTI F; GREGORETTI L; BOERI G
    Sist Nerv; 1956; 8(4):191-208. PubMed ID: 13409036
    [No Abstract]   [Full Text] [Related]  

  • 32. Dual actions of lysergic acid diethylamide tartrate (LSD), 2-bromo-D-lysergic acid diethylamide bitartrate (BOL) and methysergide on dorsal root potentials evoked by stimulation of raphe nuclei.
    Larson AA; Chinn C; Proudfit HK; Anderson EG
    J Pharmacol Exp Ther; 1981 Apr; 217(1):99-104. PubMed ID: 6110778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The experimental use of psychedelic (LSD) psychotherapy.
    Pahnke WN; Kurland AA; Unger S; Savage C; Grof S
    JAMA; 1970 Jun; 212(11):1856-63. PubMed ID: 5467681
    [No Abstract]   [Full Text] [Related]  

  • 34. LSD psychotherapy: a review of the literature and some proposals for future research.
    Clyman RC
    R I Med J; 1972 Sep; 55(9):282-6. PubMed ID: 4561308
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of LSD on body sway suggestibility in a group of hospital patients.
    Middlefell R
    Br J Psychiatry; 1967 Mar; 113(496):277-80. PubMed ID: 6029626
    [No Abstract]   [Full Text] [Related]  

  • 36. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.
    Burris KD; Sanders-Bush E
    Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The experimental use of psychedelic (LSD) psychotherapy.
    Pahnke WN; Kurland AA; Unger S; Savage C; Grof S
    Int Z Klin Pharmakol Ther Toxikol; 1971 Jun; 4(4):446-54. PubMed ID: 5566727
    [No Abstract]   [Full Text] [Related]  

  • 38. [LSD treatment. Psychotherapy with the aid of lysergic acid diethylamide].
    ANDERSEN H; KRISTENSEN KK; KNUDSEN KP
    Ugeskr Laeger; 1961 Oct; 123():1449-52. PubMed ID: 13861164
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative phenomenology of experimental mental alterations after application of LSD, benactyzine and phenmetrzine.
    Dolezal V; Hausner M
    Act Nerv Super (Praha); 1968 Oct; 10(3):280-2. PubMed ID: 5702526
    [No Abstract]   [Full Text] [Related]  

  • 40. The pharmacology of mescaline and D-lysergic acid diethylamide (LSD).
    KOELLE GB
    N Engl J Med; 1958 Jan; 258(1):25-32. PubMed ID: 13493730
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.